The “Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy” study (CONSIGN study) confirmed these results and found an overall median PFS of 2.7 months (95% CI), 2.5 months for KRAS mutant tumors, and 2.8 months for KRAS wild-type tumors [42]. This evidence concerns the gene KRAS and metastatic colorectal cancer.